Supraventricular tachycardia
• Abbreviated SVT
• “Supra” means “above”
• Supraventricular tachycardia comes from above the
ventricles
• DO NOT CONFUSE with NSVT (non-sustained
ventricular tachycardia)
• (Essentially) all narrow-complex tachycardia has a
supraventricular origin
SVT possible sites of origin
• Sinus node
• Atria
• Atrioventricular node
• His bundle
Re-entrant Automatic
Atrial Atrial flutter Automatic atrial tachycardia
Atrial fibrillation Chaotic atrial tachycardia
AV Node and AV node re-entry Junctional tachycardia
His Bundle
Location
Delta Wave
Wide QRS
Short PR
Multifocal Atrial Tachycardia
Supraventricular Tachycardia
Typical AVNRT and normal sinus rhythm after conversion.
with arrhythmia as 6%
PVCs 18%
principal diagnosis. Unspecified
4%
Atrial
Flutter
9% 34%
SSS Atrial
Fibrillation
8%
Conduction
Disease
10% VT
3% SCD
2% VF
Data source: Baily D. J Am Coll Cardiol. 1992;19(3):41A.
Atrial Flutter
• Treatment:
– Same as atrial fibrillation but often harder to slow the
ventricular rate
– Long term treatment is ablation and NOT drugs!
Sinus tachycardia
•Usually abrupt onset and offset (as opposed to gradual with sinus
tachycardia
Multifocal atrial tachycardia
segment or T wave
P waves may be invisible
Ventricular tachycardia
Ventricular tachycardia
No clear
visible P
Very fast
> 300
bpm
** This may not be ASYSTOLE
•ALWAYS check that leads are properly put on
PVC’s
Torsades de Pointes
Atrial Enlargement
• Look at P waves in leads II and V1
• Right atrial enlargement (P pulmonale)
– 1. Increased amplitude in first portion
of P wave
– 2. No change in duration of P wave
– 3. Possible right axis deviation of P wave
• Left atrial enlargement (p mitrale)
– 1. Occasionally, increased amplitude of terminal part
of P wave
– 2. More consistently, increased P wave duration
– 3. No significant axis deviation
Myocardial Infarction
• Dx – Hx, PE, serial cardiac enzymes, serial
EKG’s
• 3 EKG stages of acute MI
– 1. T wave peaks and
then inverts
– 2. ST segment elevates
– 3. Q waves appear
Q Waves
• Criteria for significant Q waves
– Q wave > 0.04 seconds in duration
– Q wave depth > ⅓ height of R wave in same QRS
complex
• Criteria for Non-Q Wave MI
– T wave inversion
– ST segment depression persisting > 48 hours in
appropriate clinical setting
Electrolyte Abnormalities on EKG
• Hyperkalemia – peaked T waves, prolonged
PR, flattened P waves, widened QRS, merging
QRS with T waves into sine wave, VF
• Hypokalemia – ST depression, flattened T
waves, U waves
• Hypocalcemia – prolonged QT interval
• Hypercalcemia – shortened QT interval
Drugs
• Digitalis
– Therapeutic levels – ST segment and T wave changes
in leads with tall R waves
– Toxic levels – tachyarrhythmias and conduction blocks;
PAT with block is most characteristic.
• Multiple drugs associated with prolonged QT
interval, U waves
– Sotalol, quinidine, procainamide, disopyramide,
amiodarone, dofetilide, dronedarone, TCA’s,
erythromycin, quinolones, phenothiazines, various
antifungals, some antihistamines, citalopram (only
prolonged QT interval – dose-dependent)
EKG ∆’s in other Cardiac Conditions
• Pericarditis – Diffuse ST segment elevations and
T wave inversions; large effusion may cause low
voltage and electrical alternans (altering QRS
amplitude or axis and wandering baseline)
• Myocarditis – conduction blocks
• Hypertrophic Cardiomyopathy – ventricular
hypertrophy, left axis deviation, septal Q waves
EKG ∆’s in Pulmonary Disorders
• COPD – low voltage, right axis deviation, and
poor R wave progression.
• Chronic cor pulmonale – P pulmonale with
right ventricular hypertrophy and
repolarization abnormalities
• Acute pulmonary embolism – right ventricular
hypertrophy with strain, RBBB, and S1Q3T3
(with T wave inversion). Sinus tachycardia and
atrial fibrillation are common.
EKG ∆’s in Pulmonary Disorders
• COPD – low voltage, right axis deviation, and
poor R wave progression.
• Chronic cor pulmonale – P pulmonale with
right ventricular hypertrophy and
repolarization abnormalities
• Acute pulmonary embolism – right ventricular
hypertrophy with strain, RBBB, and S1Q3T3
(with T wave inversion). Sinus tachycardia and
atrial fibrillation are common.
Case 1
• 53 year old caucasian female with 4 day hx
of severe central chest pain on exertion,
previously alleviated with rest; now
worsened over last 24 hours and sustained
at rest
• PMHx – DM2, HTN, hyperlipidemia
• Appears unwell, in pain, sweaty, and grey
Case 1
• Causes
» Electrolyte derangement (hypokalaemia, hypomagnesaemia,
hypocalcaemia)
» Myocardial ischaemia/infarct
» Cardiomyopathy
» Congenital (HOCM, long QT)
• Treatment
» Amiodarone
» ICDs
What can you see?
Atrial Fibrillation
Types
Paroxysmal (acute onset, spontaneous termination within 1 week)
Persistent (>7 days, can be cardioverted)
Permanent (> 1 year not terminated by cardioversion)
Causes
Cardio (HTN, valvular disease, CAD, myositis)
Pulmonary (PE, pneumonia, COPD, lung Ca)
Metabolic (hyperthyroidism)
Infection
Drugs (alcohol, illicit drugs)
AF
Investigations
Bedside – ECG/24 hour tape
Bloods – FBC, U&Es, LFTs, TFTs, coag screen
Imaging – CXR, echo
Rhythm
Cardioversion
Sotalol
Amiodarone (HF)
AF - CHA2DS2-VASc score
Thromboprophylaxi
s
C – cardiac failure (1)
H – HTN (1)
A - >75 (2, 1 if 65-74)
D – diabetes (1)
S- stroke/TIA (2)
Va – vascular disease
Sc – female (1)
0 = Low Risk
1 = Moderate risk
2 or more = high risk
MANIFESTASI KLINIK
Aritmia Asimptomatis:
Aritmia Simptomatis:
• Palpitasi/berdebar
• Pusing
• Pingsan
• Sesak nafas
• Nyeri dada
• Lemah, cepat capek
EPS procedure
• Vascular access (Venous – arterial)
• Electrode catheter (contact mapping – pacing)
• Catheter position
• Multichannel recording system +
programmable stimulator
Electrode catheter Connecting port
4 3 12 1
Dist.
Prox.
His
CS
RV
Challenge of deploying newer therapies optimally
Equality of access to treatment options..?
• Anti-arrhythmic management
– Dronedarone / Vernakalant
DDDRP
– Pacing & AV-nodal ablation
– Catheter ablation
• Stroke Prevention
- Warfarin vs Dabigatran
- Left atrial occlusion devices
Effect of rate & rhythm control on left ventricular function & cardiac dimensions in
patients with persistent atrial fibrillation: RACE Study
CRT
&
CRTD
3
2
Pacing to improve coordination of cardiac contraction
(atrio-ventricular; inter- & intra-ventricular resynchronisation)
Pacing to improve LV-function
RA
LV
RVA
Electrical
resynchronization
MADIT-CRT Trial
To assess whether CRT-D reduces mortality &
heart failure events in patients with:
NYHA class I-II
QRS > 130ms
LVEF < 30%